Piramal Enterprises Ltd.

DUBLIN, March 22, 2024 /PRNewswire/ -- The "Global Contract Development and Manufacturing Organization Market: Analysis By Type, By Product, By Sourcing, By Application, By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's offering. The global contract development and manufacturing organization (CDMO) market was valued at US$124.38 billion in 2023, and is expected to be worth US$256.90 billion in 2029. Post-millennium, the biopharmaceutical sector has advanced significantly, witnessing the development of novel drugs and blockbuster medications. The "contract development manufacturing organization (CDMO)" model has emerged in response to growing demand. CDMOs, third-party providers, specialize in developing and manufacturing production processes for pharmaceutical firms, offering support throughout the drug-making journey. These entities, primarily focused on active pharmaceutical ingredient (API) manufacturing, have surged in the past decade due to mergers and acquisitions. While larger pharmaceuticals may opt for in-house capacities, smaller firms prefer CDMO outsourcing, reducing investment risks and providing access to specialized expertise. This trend enhances the efficiency and success of drug development endeavors. The rise of innovative modalities, such as mRNA technologies, is propelling CDMOs to invest in cutting-edge manufacturing capabilities to meet evolving pharmaceutical needs. Additionally, increased outsourcing by pharmaceutical companies to streamline operations and reduce costs is boosting the CDMO sector. The growing importance of specialized services, spanning early-stage development to commercial manufacturing, underscores the expanding role of CDMOs in the entire drug development lifecycle. Furthermore, the emphasis on flexible and scalable manufacturing processes, coupled with advancements in digital technologies and data analytics, is shaping the future landscape of the CDMO market, offering efficiency and adaptability in meeting diverse and complex pharmaceutical requirements. The global CDMO market is expected to grow at a CAGR of 12.85% over the years 2024-2029. Asian CDMOs are strategically expanding their capacities, becoming pivotal in global pharmaceutical and biotechnology sectors. This growth responds to escalating demand for manufacturing services in drug development and production. Companies in China, India, and South Korea are fortifying their capabilities to serve clients worldwide. Through investments in cutting-edge facilities, advanced technologies, and workforce training, the Asian CDMOs aim to augment production capacity, flexibility, and efficiency. Historically, the industry has faced excess demand, attributed to robust development pipelines and challenges in scaling capacity. More recently, Biologics CDMO companies (particularly Samsung Biologics and Wuxi Biologics) have been seen investing in massive production capacity expansion projects. Competitive Landscape: The CDMO market is fragmented since several vendors contribute to the market share. The existence of numerous competitors in the market has an impact on service pricing, making it a direct source of competition, particularly for small-scale providers. The vendors in the market are anticipated to concentrate on offering one-stop-shop services to gain a competitive edge. Players in the market are adopting strategies such as partnerships, company expansions, innovations, and acquisitions to enhance their product offerings and gain sustainable competitive advantage. In June 2023, Catalent expanded the One Bio Suite solution, encompassing development, manufacturing, and supply for various biotechnological modalities, such as antibodies, recombinant proteins, cellular and gene therapy, and mRNA. Impact Analysis of COVID-19 and Way Forward: The COVID-19 pandemic significantly impacted the CDMO market. As the pharmaceutical industry raced to develop vaccines and treatments, CDMOs played a crucial role in providing manufacturing capabilities. Increased demand for vaccine production and the need for diversified supply chains elevated the importance of CDMOs. Despite challenges like supply chain disruptions, the CDMO market experienced growth, driven by accelerated research and development activities. Vaccine development and manufacturing activity in the CDMO market has increased in the past years, owing primarily to the industry's response to the COVID-19 pandemic. This expansion is expected to continue in the coming years as well. Increased demand for new treatments, whether for COVID-19 or other critical medications, necessitates increased production. Many sponsors collaborate with contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs) to scale up and meet commercial capacity demands in order to get treatments to patients as soon as possible. Market Segmentation Analysis: Market Segmentation Insights By Type: Chemical Drugs: Dominated the market in 2023 due to prevalence in therapeutic areas like cardiovascular diseases. Biologics: Expected to grow fastest, driven by increasing demand for innovative therapies. By Product: API/Bulk Drugs: Highest share, witnessing growth due to demand for both generic and innovative drugs. Drug Product Manufacturing: Expected to exhibit fastest CAGR, driven by increasing prevalence of chronic diseases. Packaging: Plays a significant role in the market. By Sourcing: In House: Dominated in 2023, driven by desire for control over proprietary processes and quality assurance. Outsourced: Anticipated to exhibit fastest CAGR, driven by cost-effectiveness and surge in outsourcing. By Application: Oncology: Witnessing surge due to demand for precision medicines and innovative cancer therapies. Cardiovascular Disease, Diabetes, Hormonal, Glaucoma: Significant segments in the market. By Region: Asia Pacific: Dominated in 2023, providing lucrative opportunities driven by rising pharmaceutical demand and skilled workforce. North America: Significant share, driven by stricter regulations and outsourcing trends. Europe: Plays a significant role in the market. ROW: Emerging regions contributing to market growth. Key Insights from Regional Analysis Asia Pacific: Booming market driven by rising pharmaceutical demand and skilled workforce. China dominates, but India and Singapore emerging as contenders. Bright future with continued growth and technological advancements. North America: Significant share with strict regulations ensuring quality. Rise in biopharmaceuticals and drug development pipelines driving outsourcing. Executive Order on Biotechnology and Biomanufacturing Innovation supports market growth. Market Dynamics Growth Drivers Aging Population Rising Healthcare Expenditure Increasing Pharmaceutical R&D Expenses Escalating Demand for Active Pharmaceutical Ingredient (API) Surge in Outsourcing Trends Rising Prevalence of Genetic Disorders Challenges Biotech Funding Issues Varying Regulatory Requirements Across Regions Dependence on Patents, Copyrights, Trademarks and Trade Secrets Market Trends Growing Biologics Market Rising Development of Small Molecule Drugs Bringing Orphan Drugs to Market Emerging Markets Rise in Investments and Strategic Collaborations Technological Advancement in the CDMO The key players of the global CDMO market are: Catalent Pharma Solutions Inc. Samsung Biologics Co. Ltd. WuXi AppTec Boehringer Ingelheim WuXi Biologics (Cayman) Inc. Jubilant Pharmova Limited Lonza Group AG Siegfried Holding AG Thermo Fisher Scientific Inc. FUJIFILM Holdings Corporation Recipharm AB Bushu Pharma Piramal Group (Piramal Pharma Solutions) For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

NEW YORK, Jan. 17, 2024 /PRNewswire/ -- The over-the-counter (OTC) analgesics market is expected to grow by USD 6.52 billion from 2022 to 2027. In addition, the momentum of the market will progress at a CAGR of 4.74% during the forecast period, according to Technavio Research. The market is segmented by type (internal and external), distribution channel (offline and online), and geography (North America, Europe, Asia, and Rest of World (ROW)). North America is estimated to contribute 42% to the growth of the global market during the forecast period. The growth of the North American OTC analgesics market is notably driven by several key factors, including a rise in healthcare expenditure, a high prevalence of pain-related conditions and arthritis, the robust presence of vendors within the region, and supportive government policies. Continue Reading Technavio has announced its latest market research report titled Global Over the Counter (OTC) Analgesics Market 2023-2027 This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read the Free PDF Sample Report Company Profile: AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Cardinal Health Inc., Cipla Ltd., CV Sciences Inc., Endo International Plc, GlaxoSmithKline Plc, Medterra CBD, Novartis AG, Perrigo Co. Plc, Pfizer Inc., Piramal Enterprises Ltd., Reckitt Benckiser Group Plc, Sanofi, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Weefsel Pharma, and AKUMS Bayer AG: The company offers over the counter analgesics used for chronic pain and migraine. To gain access to more company profiles available with Technavio, buy the report! Over The Counter (OTC) Analgesics Market: Segmentation Analysis By Segment - The market share growth by the internal segment is significant during the forecast period. Internal analgesics primarily serve the purpose of internal use and can be administered orally in the form of pills and liquids or inserted rectally in suppository form. Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a Free PDF Sample Report "Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021"- Technavio Over The Counter (OTC) Analgesics Market: Driver & Trend: Growing aging population globally Increasing prevalence of pain-related conditions Growing number of mergers and acquisitions (M&A) activities The growing aging population across the world drives the market growth. The global demographic landscape is undergoing a noteworthy transformation, primarily driven by the growing aging population, which is a significant contributor to market growth. The Over-the-Counter (OTC) Analgesics Market faces the challenge of balancing consumer healthcare needs with safety and side effects, particularly concerning Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) like Ibuprofen, Naproxen, and Aspirin, as well as Acetaminophen (Paracetamol). Innovations in product forms such as gel capsules, effervescent tablets, and topical analgesics, including pain relief creams, offer varied options for pain management, from migraine relief to menstrual and muscle pain relief, and solutions for arthritis pain and fever reducers. However, the rise in self-medication trends, influenced by consumer preferences and pain management education, intensifies the need for a stringent regulatory framework. This includes overseeing the prescription to OTC switch and monitoring analgesic combinations. The market also sees a shift towards herbal and natural remedies, challenging traditional OTC analgesic brands. Adult analgesics and pediatric pain relievers must adapt to these shifts. Moreover, the expansion of distribution channels from drugstore chains to online pharmacies requires innovative packaging solutions and accurate market forecasting. This dynamic market landscape demands a balance between meeting consumer health needs and ensuring responsible use of OTC analgesics. Identify key trends, drivers, and challenges in the market. Download a sample to gain access to this information. Related Reports: The renal anemia therapeutics market size is estimated to grow by USD 2.08 billion, at a CAGR of 7.59% between 2023 and 2028. The equine supplement products market size is estimated to grow by USD 20,352.14 at a CAGR of 4.19% between 2023 and 2028. What are the key data covered in this over the counter (OTC) analgesics market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the over the counter (OTC) analgesics market between 2022 and 2027. Precise estimation of the over the counter (OTC) analgesics market size and its contribution to the market in focus on the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth of the over the counter (OTC) analgesics market across North America, Europe, Asia, and ROW A thorough analysis of the market's competitive landscape and detailed information about companies Comprehensive analysis of factors that will challenge the growth of over the counter (OTC) analgesics market players. ToC: Executive Summary Market Landscape Market Sizing Historic Market Sizes Five Forces Analysis Market Segmentation by Type Market Segmentation by Distribution Channel Market Segmentation by Geography Customer Landscape Geographic Landscape Drivers, Challenges, & Trends Company Landscape Company Analysis Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

DUBLIN, Aug. 23, 2023 /PRNewswire/ -- The "Pregnancy Care Products: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Pregnancy Care Products is on a growth trajectory, with an estimated value of $26 million in 2022 and a projected size of $39.6 million by 2030. The market is expected to experience a steady Compound Annual Growth Rate (CAGR) of 5.4% over the analysis period from 2022 to 2030. Among the key segments, Stretch Mark Minimizer is anticipated to lead the growth with a projected CAGR of 5.4%, reaching $11.7 million by the end of the analysis period. U.S. and China Lead the Way The Pregnancy Care Products market in the U.S. is estimated at $6.9 million in 2022. China, the world's second-largest economy, is forecasted to reach a market size of $9 million by 2030, driven by a CAGR of 8.3% during the period from 2022 to 2030. Notable growth is also expected in Japan and Canada, with anticipated CAGRs of 3.2% and 4.2% respectively over the same period. In Europe, Germany is projected to experience growth at approximately 3.9% CAGR. Market Scope The data provided offers a comprehensive analysis of the global Pregnancy Care Products market, focusing on various geographic regions including the USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East, and Africa markets. The analysis covers the years from 2014 to 2030 and provides insights into annual sales figures in US$ million along with the percentage Compound Annual Growth Rate (CAGR) for different types of pregnancy care products, including Stretch Mark Minimizer, Body Restructuring Gel, Toning/Firming Lotion, Nipple Protection Cream, Breast Cream, and Other Types. Similar to previous examples, the data is presented through multiple tables, offering insights into recent, current, and future trends in the Pregnancy Care Products market. The analysis also includes a historic review and a 16-year perspective, providing a percentage breakdown of value sales for specified regions for the years 2014, 2023, and 2030. This data aims to provide a comprehensive understanding of the trends, growth opportunities, and market dynamics in the global Pregnancy Care Products industry across different geographic regions and product types. Market Overview Influencer Market Insights World Market Trajectories Pregnancy Care Products - Global Key Competitors Percentage Market Share in 2022 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) Impact of Covid-19 and a Looming Global Recession What's New for 2023? Special coverage includes insights on the Russia-Ukraine war, global inflation, easing of the zero-Covid policy in China and its 'bumpy' reopening, supply chain disruptions, global trade tensions, and the risk of recession. Additional features include information on global competitiveness, key competitor percentage market shares, market presence across multiple geographies, online interactive peer-to-peer collaborative bespoke updates, access to digital archives, and the publisher's Research Platform, along with complimentary updates for one year. Select Competitors A selection of companies featured in the Pregnancy Care Products market report includes: Clarins Group E.T. Browne Drug Co., Inc. (Palmer's) Laboratoires Expanscience Mankind Pharma Ltd. Nine Naturals LLC Noodle & Boo, LLC Piramal Enterprises Ltd. Procter & Gamble Company, The Quidel Corporation Key Attributes: For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets